Literature DB >> 33435150

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.

Valentina R Minciacchi1, Rahul Kumar1, Daniela S Krause1,2,3,4,5.   

Abstract

Chronic myeloid leukemia (CML) has been a "model disease" with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after targeted therapies, we describe here the journey of CML, focusing on molecular pathways relating to signaling, metabolism and the bone marrow microenvironment. We highlight current strategies for combination therapies aimed at eradicating the CML stem cell; hopefully the final destination of this long voyage.

Entities:  

Keywords:  bone marrow microenvironment; chronic myeloid leukemia; combination therapies; history; metabolism; targeted therapy

Year:  2021        PMID： 33435150      PMCID： PMC7827482          DOI： 10.3390/cells10010117

Source DB:  PubMed          Journal:  Cells        ISSN： 2073-4409            Impact factor:   6.600


  194 in total

1.  Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Authors:  Mathilde Ruggiu; Florence Oberkampf; David Ghez; Pascale Cony-Makhoul; Florence Beckeriche; Isabelle Cano; Anne L Taksin; Omar Benbrahim; Stéphanie Ghez; Hassan Farhat; Sophie Rigaudeau; Noémie de Gunzburg; Diane Lara; Christine Terre; Victoria Raggueneau; Isabel Garcia; Marc Spentchian; Stéphane De Botton; Philippe Rousselot
Journal:  Leuk Lymphoma       Date:  2017-11-28

2.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

3.  Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

Authors:  Andreas Burchert; Martin C Müller; Philippe Kostrewa; Philipp Erben; Tilman Bostel; Simone Liebler; Rüdiger Hehlmann; Andreas Neubauer; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

4.  Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.

Authors:  H Honda; T Ushijima; K Wakazono; H Oda; Y Tanaka; S i Aizawa; T Ishikawa; Y Yazaki; H Hirai
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

Review 5.  Chronic myeloid leukemia as an immunological target.

Authors:  S H Lim; S Coleman
Journal:  Am J Hematol       Date:  1997-01       Impact factor: 10.047

6.  The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.

Authors:  Mariella D'Adda; Mirko Farina; Francesca Schieppati; Erika Borlenghi; Chiara Bottelli; Elisa Cerqui; Samantha Ferrari; Doriana Gramegna; Chiara Pagani; Angela Passi; Adriana Maifredi; Alessandra Tucci; Maria A Capucci; Giuseppina Ruggeri; Giuseppe Rossi
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

7.  Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Authors:  Eva Nievergall; Hayley S Ramshaw; Agnes S M Yong; Mark Biondo; Samantha J Busfield; Gino Vairo; Angel F Lopez; Timothy P Hughes; Deborah L White; Devendra K Hiwase
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

Review 8.  The growing landscape of lysine acetylation links metabolism and cell signalling.

Authors:  Chunaram Choudhary; Brian T Weinert; Yuya Nishida; Eric Verdin; Matthias Mann
Journal:  Nat Rev Mol Cell Biol       Date:  2014-08       Impact factor: 94.444

Review 9.  Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

Authors:  L S Steelman; S L Abrams; J Whelan; F E Bertrand; D E Ludwig; J Bäsecke; M Libra; F Stivala; M Milella; A Tafuri; P Lunghi; A Bonati; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-03-13       Impact factor: 11.528

10.  Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.

Authors:  H Zhou; P Y Mak; H Mu; D H Mak; Z Zeng; J Cortes; Q Liu; M Andreeff; B Z Carter
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528
View more
  16 in total

Review 1.  Non-coding RNAs: are they the protagonist or antagonist in the regulation of leukemia?

Authors:  Mrinnanda Bhattacharya; Ravi Kumar Gutti
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 2.  The inflammasomes: crosstalk between innate immunity and hematology.

Authors:  Valéria de Freitas Dutra; Vinicius Nunes Cordeiro Leal; Alessandra Pontillo
Journal:  Inflamm Res       Date:  2022-10-20       Impact factor: 6.986

3.  Emerging landscape of circHIPK3 and its role in cancer and other diseases (Review).

Authors:  Qi Shao; Yong Huang; Cai Zhang; Xiaochan Gao; Shiyang Gao
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

4.  Blood cancer health disparities in the United States Hispanic population.

Authors:  Alfonso E Bencomo-Alvarez; Andres J Rubio; Mayra A Gonzalez; Anna M Eiring
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-04-08

5.  Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations.

Authors:  Muhammad Asif; Abrar Hussain; Abdul Wali; Nazeer Ahmed; Irfan Ali; Zafar Iqbal; Muhammad Amir; Muhammad Shafiq; Mahmood Rasool
Journal:  Anal Cell Pathol (Amst)       Date:  2021-08-12       Impact factor: 2.916

6.  The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients.

Authors:  Li-Rong Yang; Zhu-Ying Lin; Qing-Gang Hao; Tian-Tian Li; Yun Zhu; Zhao-Wei Teng; Jun Zhang
Journal:  Cancer Cell Int       Date:  2022-01-07       Impact factor: 5.722

Review 7.  Platelet Function, Role in Thrombosis, Inflammation, and Consequences in Chronic Myeloproliferative Disorders.

Authors:  Lisa Repsold; Anna Margaretha Joubert
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

Review 8.  Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?

Authors:  Bilal Abdulmawjood; Beatriz Costa; Catarina Roma-Rodrigues; Pedro V Baptista; Alexandra R Fernandes
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

9.  Aberrant Expressional Profiling of Small RNA by Cold Atmospheric Plasma Treatment in Human Chronic Myeloid Leukemia Cells.

Authors:  Bo Guo; Wen Li; Yijie Liu; Dehui Xu; Zhijie Liu; Chen Huang
Journal:  Front Genet       Date:  2022-02-03       Impact factor: 4.599

10.  Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms.

Authors:  Ken-Hong Lim; Shinobu Matsuura; Bing Xu
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.